Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 264

1.

Insulin resistance and Alzheimer's disease.

de la Monte SM.

BMB Rep. 2009 Aug 31;42(8):475-81. Review.

PMID:
19712582
[PubMed - indexed for MEDLINE]
Free Article
2.

Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

de la Monte SM, Longato L, Tong M, Wands JR.

Curr Opin Investig Drugs. 2009 Oct;10(10):1049-60. Review.

PMID:
19777393
[PubMed - indexed for MEDLINE]
3.

Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

de la Monte SM.

Drugs. 2012 Jan 1;72(1):49-66. doi: 10.2165/11597760-000000000-00000. Review.

PMID:
22191795
[PubMed - indexed for MEDLINE]
4.

Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus.

Moroz N, Tong M, Longato L, Xu H, de la Monte SM.

J Alzheimers Dis. 2008 Sep;15(1):29-44.

PMID:
18780965
[PubMed - indexed for MEDLINE]
5.

Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease.

de la Monte SM, Tong M.

J Alzheimers Dis. 2009;17(4):817-25. doi: 10.3233/JAD-2009-1098.

PMID:
19542621
[PubMed - indexed for MEDLINE]
6.

Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.

Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM.

J Alzheimers Dis. 2006 Mar;9(1):13-33.

PMID:
16627931
[PubMed - indexed for MEDLINE]
7.

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.

Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM.

J Alzheimers Dis. 2005 Dec;8(3):247-68.

PMID:
16340083
[PubMed - indexed for MEDLINE]
8.

Insulin resistance and Alzheimer's disease: molecular links & clinical implications.

Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB.

Curr Alzheimer Res. 2008 Oct;5(5):438-47.

PMID:
18855585
[PubMed - indexed for MEDLINE]
9.

Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.

de la Monte SM, Wands JR.

J Alzheimers Dis. 2005 Feb;7(1):45-61. Review.

PMID:
15750214
[PubMed - indexed for MEDLINE]
10.

Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease.

de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR.

J Alzheimers Dis. 2006 Sep;10(1):89-109. Review.

PMID:
16988486
[PubMed - indexed for MEDLINE]
11.

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM.

J Alzheimers Dis. 2005 Feb;7(1):63-80.

PMID:
15750215
[PubMed - indexed for MEDLINE]
12.

The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease.

Freude S, Schilbach K, Schubert M.

Curr Alzheimer Res. 2009 Jun;6(3):213-23. Review.

PMID:
19519303
[PubMed - indexed for MEDLINE]
13.

Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation.

Craft S.

Neurobiol Aging. 2005 Dec;26 Suppl 1:65-9. Epub 2005 Nov 2. Review.

PMID:
16266773
[PubMed - indexed for MEDLINE]
14.

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

Craft S.

Curr Alzheimer Res. 2007 Apr;4(2):147-52. Review.

PMID:
17430239
[PubMed - indexed for MEDLINE]
15.

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.

Zhao WQ, Townsend M.

Biochim Biophys Acta. 2009 May;1792(5):482-96. doi: 10.1016/j.bbadis.2008.10.014. Epub 2008 Nov 5. Review.

PMID:
19026743
[PubMed - indexed for MEDLINE]
Free Article
16.

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Watson GS, Craft S.

CNS Drugs. 2003;17(1):27-45. Review.

PMID:
12467491
[PubMed - indexed for MEDLINE]
17.

Ceramide-mediated insulin resistance and impairment of cognitive-motor functions.

de la Monte SM, Tong M, Nguyen V, Setshedi M, Longato L, Wands JR.

J Alzheimers Dis. 2010;21(3):967-84. doi: 10.3233/JAD-2010-091726.

PMID:
20693650
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis.

Bosco D, Fava A, Plastino M, Montalcini T, Pujia A.

J Cell Mol Med. 2011 Sep;15(9):1807-21. doi: 10.1111/j.1582-4934.2011.01318.x. Review.

PMID:
21435176
[PubMed - indexed for MEDLINE]
19.

Brain metabolic dysfunction at the core of Alzheimer's disease.

de la Monte SM, Tong M.

Biochem Pharmacol. 2014 Apr 15;88(4):548-59. doi: 10.1016/j.bcp.2013.12.012. Epub 2013 Dec 28. Review.

PMID:
24380887
[PubMed - indexed for MEDLINE]
20.

Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed.

de la Monte SM.

J Alzheimers Dis. 2012;30 Suppl 2:S231-49. doi: 10.3233/JAD-2012-111727. Review.

PMID:
22337830
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk